{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:39:55Z","timestamp":1771925995311,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"51","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100005416","name":"Research Council of Norway","doi-asserted-by":"crossref","award":["192477"],"award-info":[{"award-number":["192477"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.vaccine.2013.09.044","type":"journal-article","created":{"date-parts":[[2013,10,10]],"date-time":"2013-10-10T23:26:34Z","timestamp":1381447594000},"page":"6097-6106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Preclinical immunogenicity and functional activity studies of an A+W meningococcal outer membrane vesicle (OMV) vaccine and comparisons with existing meningococcal conjugate- and polysaccharide vaccines"],"prefix":"10.1016","volume":"31","author":[{"given":"G.","family":"Tunheim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Arnemo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.M.","family":"N\u00e6ss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c5.K.","family":"Fjeldheim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Nome","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Bolstad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Aase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Mandiarote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Norheim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Rosenqvist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl.","key":"10.1016\/j.vaccine.2013.09.044_bib0005","first-page":"1","article-title":"Cerebrospinal meningitis in Africa","volume":"28","author":"Lapeyssonnie","year":"1963","journal-title":"Bulletin of the World Health Organization"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2013.09.044_bib0010","doi-asserted-by":"crossref","first-page":"B13","DOI":"10.1016\/j.vaccine.2009.04.062","article-title":"Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution","volume":"27","author":"LaForce","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.09.044_bib0015","doi-asserted-by":"crossref","first-page":"e19513","DOI":"10.1371\/journal.pone.0019513","article-title":"Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso","volume":"6","author":"Delrieu","year":"2011","journal-title":"PLOS ONE"},{"key":"10.1016\/j.vaccine.2013.09.044_bib0020","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1128\/CMR.19.1.142-164.2006","article-title":"Prospects for vaccine prevention of meningococcal infection","volume":"19","author":"Harrison","year":"2006","journal-title":"Clinical Microbiology Reviews"},{"key":"10.1016\/j.vaccine.2013.09.044_bib0025","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1136\/bmj.1.6123.1317","article-title":"Prevention of secondary cases of meningococcal disease in household contacts by vaccination","volume":"1","author":"Greenwood","year":"1978","journal-title":"British Medical Journal"},{"key":"10.1016\/j.vaccine.2013.09.044_bib0030","doi-asserted-by":"crossref","first-page":"715","DOI":"10.4161\/hv.19619","article-title":"Development of a group A meningococcal conjugate vaccine, MenAfriVac(TM)","volume":"8","author":"Frasch","year":"2012","journal-title":"Human Vaccines & Immunotherapeutics"},{"key":"10.1016\/j.vaccine.2013.09.044_bib0035","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1003812","article-title":"Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans","volume":"364","author":"Sow","year":"2011","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.vaccine.2013.09.044_bib0040","doi-asserted-by":"crossref","first-page":"6456","DOI":"10.1016\/j.vaccine.2012.08.004","article-title":"Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children aged 2\u201310 years: a phase II\/III double-blind randomized controlled trial","volume":"30","author":"Hirve","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.09.044_bib0045","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/cid\/cis892","article-title":"Impact of the serogroup A meningococcal conjugate vaccine. MenAfriVac, on carriage and herd immunity","volume":"56","author":"Kristiansen","year":"2013","journal-title":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America"},{"key":"10.1016\/j.vaccine.2013.09.044_bib0050","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1473-3099(12)70168-8","article-title":"Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data","volume":"12","author":"Novak","year":"2012","journal-title":"The Lancet Infectious Diseases"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2013.09.044_bib0055","doi-asserted-by":"crossref","first-page":"B3","DOI":"10.1016\/j.vaccine.2009.04.071","article-title":"Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis","volume":"27","author":"Holst","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.09.044_bib0060","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.4161\/hv.24129","article-title":"Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future","volume":"9","author":"Holst","year":"2013","journal-title":"Human Vaccines & Immunotherapeutics"},{"key":"10.1016\/j.vaccine.2013.09.044_bib0065","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1365-3083.2012.02709.x","article-title":"An outer membrane vesicle vaccine for prevention of serogroup A and W-135 meningococcal disease in the African meningitis belt","volume":"76","author":"Norheim","year":"2012","journal-title":"Scandinavian Journal of Immunology"},{"key":"10.1016\/j.vaccine.2013.09.044_bib0070","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1128\/JCM.44.3.861-871.2006","article-title":"Characterization of Neisseria meningitidis isolates from recent outbreaks in Ethiopia and comparison with those recovered during the epidemic of 1988 to 1989","volume":"44","author":"Norheim","year":"2006","journal-title":"Journal of Clinical Microbiology"},{"key":"10.1016\/j.vaccine.2013.09.044_bib0075","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1084\/jem.20020407","article-title":"NadA, a novel vaccine candidate of Neisseria meningitidis","volume":"195","author":"Comanducci","year":"2002","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/j.vaccine.2013.09.044_bib0080","article-title":"Combined meningococcal serogroup A and W outer-membrane vesicles activate cell-mediated immunity and long-term memory responses against non-covalent capsular polysaccharide A","author":"Romeu","year":"2013","journal-title":"Immunologic Research"},{"key":"10.1016\/j.vaccine.2013.09.044_bib0085","first-page":"81","article-title":"Outer membrane protein vesicle vaccines for meningococcal disease","volume":"66","author":"Frasch","year":"2001","journal-title":"Methods in Molecular Medicine"},{"key":"10.1016\/j.vaccine.2013.09.044_bib0090","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0092-1157(89)90017-6","article-title":"Measurements of lipopolysaccharide (endotoxin) in meningococcal protein and polysaccharide preparations for vaccine usage","volume":"17","author":"Tsai","year":"1989","journal-title":"Journal of Biological Standardization"},{"key":"10.1016\/j.vaccine.2013.09.044_bib0095","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1128\/JCM.30.1.154-159.1992","article-title":"Multicenter comparison of levels of antibody to the Neisseria meningitidis group A capsular polysaccharide measured by using an enzyme-linked immunosorbent assay","volume":"30","author":"Carlone","year":"1992","journal-title":"Journal of Clinical Microbiology"},{"key":"10.1016\/j.vaccine.2013.09.044_bib0100","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1128\/CVI.00252-07","article-title":"Specificity of subcapsular antibody responses in Ethiopian patients following disease caused by serogroup A meningococci","volume":"15","author":"Norheim","year":"2008","journal-title":"Clinical and Vaccine Immunology"},{"key":"10.1016\/j.vaccine.2013.09.044_bib0105","first-page":"275","article-title":"Immunoblot analysis of sera from patients and vaccinees","volume":"66","author":"Wedege","year":"2001","journal-title":"Methods in Molecular Medicine"},{"key":"10.1016\/j.vaccine.2013.09.044_bib0110","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/CDLI.4.2.156-167.1997","article-title":"Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group","volume":"4","author":"Maslanka","year":"1997","journal-title":"Clinical and Diagnostic Laboratory Immunology"},{"key":"10.1016\/j.vaccine.2013.09.044_bib0115","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/S0264-410X(02)00774-0","article-title":"Comparison of functional immune responses in humans after intranasal and intramuscular immunisations with outer membrane vesicle vaccines against group B meningococcal disease","volume":"21","author":"Aase","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.09.044_bib0120","series-title":"17th international pathogenic conference","article-title":"P227 Scale-up of process for GMP production of a serogroup A and W135 meningococcal outer membrane vesicle vaccine for Africa [abstract]","author":"Garcia","year":"2010"},{"key":"10.1016\/j.vaccine.2013.09.044_bib0125","series-title":"17th international pathogenic conference","article-title":"P229 characterization and immunogenicity evaluation of serogroup A and W135 outer membrane vesicles derived from growth in modified Frantz and Catlin medium [abstract]","author":"Reyes","year":"2010"},{"key":"10.1016\/j.vaccine.2013.09.044_bib0130","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1016\/j.vaccine.2005.02.021","article-title":"Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis","volume":"23","author":"Norheim","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.09.044_bib0135","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection \u2013 serum bactericidal antibody activity","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.09.044_bib0140","first-page":"67","article-title":"Production, characterization and control of MenB-vaccine Folkehelsa: an outer membrane vesicle vaccine against group B meningococcal disease","volume":"14","author":"Fredriksen","year":"1991","journal-title":"NIPH Annals"},{"key":"10.1016\/j.vaccine.2013.09.044_bib0145","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.vaccine.2008.11.065","article-title":"Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa","volume":"27","author":"Lee","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.09.044_bib0150","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/0264-410X(92)90091-W","article-title":"Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C","volume":"10","author":"Costantino","year":"1992","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.09.044_bib0155","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.vaccine.2005.09.043","article-title":"Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control","volume":"24","author":"Thornton","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.09.044_bib0160","series-title":"Assessment report for menveo common name: meningococcal group A, C, W135 and Y conjugate vaccine procedure no. EMEA\/H\/C\/001095 assessment report","year":"2009"},{"key":"10.1016\/j.vaccine.2013.09.044_bib0165","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1016\/j.vaccine.2003.11.047","article-title":"Immunogenicity and bactericidal activity in mice of an outer membrane protein vesicle vaccine against Neisseria meningitidis serogroup A disease","volume":"22","author":"Norheim","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.09.044_bib0170","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1086\/656741","article-title":"Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy","volume":"51","author":"Findlow","year":"2010","journal-title":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America"},{"key":"10.1016\/j.vaccine.2013.09.044_bib0175","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1128\/CVI.00070-12","article-title":"Analysis of the bactericidal response to an experimental Neisseria meningitidis vesicle vaccine","volume":"19","author":"Moran","year":"2012","journal-title":"Clinical and Vaccine Immunology: CVI"},{"key":"10.1016\/j.vaccine.2013.09.044_bib0180","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.vaccine.2012.12.022","article-title":"Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa?","volume":"31","author":"Hong","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.09.044_bib0185","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1016\/j.vaccine.2013.04.036","article-title":"Emergence of serogroup X meningococcal disease in Africa: need for a vaccine","volume":"31","author":"Xie","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.09.044_bib0190","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/jama.281.16.1520","article-title":"Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile","volume":"281","author":"Tappero","year":"1999","journal-title":"JAMA: The Journal of the American Medical Association"},{"key":"10.1016\/j.vaccine.2013.09.044_bib0195","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.1128\/JCM.43.10.5129-5135.2005","article-title":"Molecular epidemiology of Neisseria meningitidis isolated in the African Meningitis Belt between 1988 and 2003 shows dominance of sequence type 5 (ST-5) and ST-11 complexes","volume":"43","author":"Nicolas","year":"2005","journal-title":"Journal of Clinical Microbiology"},{"key":"10.1016\/j.vaccine.2013.09.044_bib0200","doi-asserted-by":"crossref","first-page":"e46019","DOI":"10.1371\/journal.pone.0046019","article-title":"Molecular characterization of invasive meningococcal isolates from countries in the African meningitis belt before introduction of a serogroup A conjugate vaccine","volume":"7","author":"Caugant","year":"2012","journal-title":"PLOS ONE"},{"key":"10.1016\/j.vaccine.2013.09.044_bib0205","doi-asserted-by":"crossref","first-page":"e1302","DOI":"10.1371\/journal.pntd.0001302","article-title":"Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development","volume":"5","author":"Pajon","year":"2011","journal-title":"PLoS Neglected Tropical Diseases"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1301298X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1301298X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T17:40:36Z","timestamp":1596649236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1301298X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":41,"journal-issue":{"issue":"51","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0264410X1301298X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.09.044","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical immunogenicity and functional activity studies of an A+W meningococcal outer membrane vesicle (OMV) vaccine and comparisons with existing meningococcal conjugate- and polysaccharide vaccines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.09.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}